Nano Dimension to Buy Infinite Epigenetics in $890 Million Stock Deal
The acquisition leverages Nano Dimension's capital base to enter the high-growth healthcare AI sector.
Nano Dimension Ltd. (NNDM) agreed to acquire Infinite Epigenetics, Inc. in an all-stock transaction valued at $890 million.
The deal represents a 20% premium to Nano Dimension’s estimated net cash at closing. The transaction remains subject to the completion of satisfactory due diligence, the negotiation of a definitive agreement, and the approval of both companies' boards of directors and shareholders.
Nano Dimension said the combination would deploy its capital base, Nasdaq platform, and strategic flexibility into a high-growth healthcare AI opportunity. The company indicated that the move follows a multi-month review of approximately 20 potential opportunities across various sectors conducted alongside financial advisor Houlihan Lokey.
“Infinite Epigenetics represented the most attractive opportunity for us to enhance shareholder value,” David Stehlin, Chief Executive Officer of Nano Dimension, said. “The company checked the key boxes we were looking for: a proven technology platform with: revenue-generating operations; a large, growing addressable market; world-class customers and partners; and a strong leadership team, experienced board members, and highly accomplished investors. We believe Infinite Epigenetics has the potential to become a category-defining company at the intersection of healthcare, biological data and AI, and that the proposed business combination would create a clear and compelling path for long-term shareholder value creation”.
The acquisition aligns Nano Dimension with a broader trend of consolidation and scaling in the biological data and diagnostics space, mirroring the trajectories of companies such as Exact Sciences, GRAIL, and Tempus AI.
Closing is contingent upon regulatory approvals and other customary conditions.